B gepatiti yadroviy antigeniga qarshi antitanalar, IgM (anti-HBc IgM)
Kod:17016|CPT:86705|LOINC:24113-3
| Kabi | B gepatiti yadroviy antigeniga qarshi antitanalar, IgM |
|---|
Tahlil ma'lumotlari
Tadqiqot usuli
- Immunokimyoluminometrik analiz (ICMA)
- Kimyoluminessent immunoanaliz (CLIA)
Kutilayotgan natija topshirish vaqti
1 kun
Maxsus tayyorlik
- Stop high-dose biotin (vitamin B7/B8, vitamin H, coenzyme R) for at least 72 hours before the blood draw
- Do not smoke during the 30 minutes before specimen collection
Qanday foydalanish
B gepatiti yadroviy antigeniga qarshi antitanalar, IgM (anti-HBc IgM; HBV yadroviy antitanasi, IgM) testi infeksiyaning klinik bosqichini tavsiflash uchun HBVning boshqa serologik markerlari bilan birga qo‘llaniladi. U o‘tkir virusli gepatitdan shubhalangan bemorlarni baholashda yordam beradi, sog‘ayish (konvalestsensiya) bosqichini surunkali infeksiyaga evolyutsiyadan farqlashga ko‘maklashadi va boshqa HBV markerlari bilan birga ko‘rilganda, surunkali B gepatitidagi kuchayishlarni monitoring qilishga hissa qo‘shadi.
Cheklovlar
B gepatiti virusi (HBV) — qon va tana suyuqliklari orqali yuqadigan DNK-virusi bo‘lib, o‘tkir hamda surunkali gepatitning global sabablaridan biri bo‘lib qolmoqda. Yadroviy antigen (HBcAg) kuchli immunogen hisoblanadi; anti-HBc IgM erta, taxminan infeksiyadan 3–5 hafta o‘tib paydo bo‘ladi. Kech prodromal fazada u yagona spetsifik marker bo‘lishi mumkin, so‘ng konvalestsensiya davrida odatda kamayadi, anti-HBc IgG esa yillar davomida saqlanib qolishi mumkin. Taxminan o‘tkir HBV holatlarining 9% ida anti-HBc IgM kasallikning dastlabki ikki haftasida manfiy bo‘lishi mumkin, shuning uchun noaniq vaziyatlarda testni takrorlash maqsadga muvofiq. Anti-HBc IgM aniqlanmagan holda HBsAg aniqlanishi surunkali infeksiyaga mos keladi, surunkali HBVda anti-HBc IgM paydo bo‘lishi esa kuchayishni ko‘rsatadi. Reaktiv anti-HBc IgM natijasi boshqa gepatit viruslari bilan qo‘shma infeksiyani istisno etmaydi; HBsAg musbat, gepatit simptomlari mavjud, ammo anti-HBc IgM yo‘q bo‘lgan bemorlarda alternativ etiologiyalar (masalan, non-A, non-B gepatit) yoki D gepatiti virusining superinfeksiyasi ko‘rib chiqilishi lozim.
| O'lchov birligi | qualitative | ||||
|---|---|---|---|---|---|
| Referens oraliq |
| ||||
| Ko'rsatmalar | Assessment of suspected acute viral hepatitis when HBsAg is nonreactive or other viral hepatitis serologies have not yet become positive, Staging and longitudinal follow-up of hepatitis B infection in combination with complementary HBV serologic markers |
Namunangiz talablari
| Namunangiz | Zardob |
|---|---|
| Container | Oltin/yo'lbars qopqoqli probirka (SST, gel ajratgich) |
| Hajm | 1 mL (min 0.4 mL) |
| Saqlash tayyorlik | Xona harorati, Sovutilgan, Muzlatilgan |
References
Abara WE, Qaseem A, Schillie S, et al. Hepatitis B Vaccination, Screening, and Likage to Care: Best Practice Advice from American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2017 Dec 5;167(11):794-804. PubMed 29159414
Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States. Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018 Jan 12;67(1):1-31. PubMed 29939980
Terrault NA, Lok ASF, McMahon BJ, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018 Apr;67(4):1560-1599. PubMed 29405329
Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137. PubMed 26042815
Harrison's Principles of Internal Medicine. 16th ed. New York: McGraw-Hill; 2005: 1822-1855.